INTELLIA THERAPEUTICS INC. - COMMON STOCK

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

16 4 2024 08:45:16 提供 NetDania Notify

NetDania - New 12 months Low: INTELLIA THERAPEUTICS INC. - COMMON STOCK

15 4 2024 13:45:30 提供 NetDania Notify

Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy

18 3 2024 06:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress

22 2 2024 06:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis

15 2 2024 06:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates

14 2 2024 06:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine

31 1 2024 16:00:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones

04 1 2024 15:01:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

14 11 2023 06:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

09 11 2023 06:30:00 提供 Nasdaq GlobeNewswire

Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting

02 11 2023 06:00:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis and Hold Conference Call to Discuss Third Quarter 2023 Earnings in November

26 10 2023 06:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

18 10 2023 06:00:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

13 10 2023 07:38:43 提供 Nasdaq GlobeNewswire

Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases

03 10 2023 06:00:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress

03 8 2023 06:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2023 Earnings and Company Updates

27 7 2023 06:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)

11 6 2023 07:30:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics Announces Retirement of Jean-François Formela, M.D. From its Board of Directors

05 6 2023 15:01:00 提供 Nasdaq GlobeNewswire

Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023

31 5 2023 06:30:00 提供 Nasdaq GlobeNewswire